Company: CDT
Filing Date: 2025-12-12
Form Type: S-8 POS
Source: 0001493152-25-027522
Chunk: 21

Company: CDT Equity Inc.
Filing Date: 2025-12-12
Form: S-8 POS
Chunk 21
---
 Stockholders will sell any or all the Shares under this Reoffer Prospectus. Further, we cannot assure you that the Selling Stockholders will not transfer, distribute, devise or gift the Shares by other means not described in this Reoffer Prospectus. In addition, any Shares covered by this Reoffer Prospectus that qualify for sale under Rule 144 of the Securities Act may be sold under Rule 144 rather than under this Reoffer Prospectus. The Shares may be sold in some states only through registered or licensed brokers or dealers. In addition, in some states the Shares may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification is available and complied with.

The Selling Stockholders and any other person participating in the sale of the Shares will be subject to the Exchange Act. The Exchange Act rules include, without limitation, Regulation M, which may limit the timing of purchases and sales of any of the Shares by the Selling Stockholders and any other person. In addition, Regulation M may restrict the ability of any person engaged in the distribution of the Shares to engage in market-making activities with respect to the particular securities being distributed. This may affect the marketability of the Shares and the ability of any person or entity to engage in market-making activities with respect to the Shares.

Once sold under the registration statement of which this Reoffer Prospectus forms a part, the Shares covered by this Reoffer Prospectus will be freely tradable in the hands of persons other than our affiliates.

| 19 |

<div align='center'>LEGAL MATTERS</div>

The validity of the securities being offered by this prospectus will be passed upon for us by Thompson Hine LLP, New York, New York.

<div align='center'>EXPERTS</div>

The consolidated financial statements of CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc., as of and for the years ended December 31, 2024 and 2023, incorporated by reference in this reoffer prospectus to the Annual Report on Form 10-K for the year ended December 31, 2024, have been so incorporated in reliance on the report of Marcum LLP, an independent registered public accounting firm, as stated in its report thereon, and which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, and are included in reliance upon such report and upon the authority of such firm as experts in accounting and auditing.

<div align='center'>WHERE YOU CAN FIND ADDITIONAL INFORMATION</div>

We file